IART · Integra LifeSciences Holdings Corporation

The leadership transition at Integra LifeSciences features the return of Dr. Stuart M. Essig, a veteran leader with prior CEO tenure from 1997-2012 and deep company knowledge as Chairman since 2012 and recent Executive Chairman. His appointment signals continuity and leverages his familiarity with operations, quality remediation, and strategic priorities amid ongoing transformation efforts. Compensation is competitive for the role, with a substantial $8 million initial equity package to align incentives, plus robust severance protections including full equity acceleration. Ms. Poul's departure includes tailored separation payments tied to her prior agreement, acknowledging contributions to portfolio prioritization and quality improvements. The creation of the Chief Commercial Officer role for Michael McBreen, promoted internally, underscores emphasis on revenue growth and customer focus, with both divisions reporting to him. This move aims to sharpen commercial execution and market responsiveness, positioning the company for sustained performance under Essig's mandate.